US 5,393,534 A · Liver-derived tumor cell growth inhibitor

Abstract

A factor has been purified from rat liver homogenate which displays preferential growth inhibitory effects on non-liver metastasizing tumor cells. The purification steps include heat treatment, ammonium sulfate precipitation, anion exchange chromatography, hydrophobic interaction chromatography, cation exchange chromatography, gel filtration chromatography, and preparative isoelectric focusing. The growth inhibitor obtained has an apparent M.sub.r of 38 kD to 40 kD and a pI of 9.1, it is not affected by reducing agents, and displays no biological TGF-b activity. This inhibitor exhibits less antiproliferative effect on liver metastasizing cells than on their non-liver metastasizing counterparts in two tumor systems: the murine RAW117 large cell lymphoma, and the human A375 melanoma.

Claims14

Dependent claims

A purified tumor growth inhibitor having the following properties:

(a) isolatable from liver cells;
(b) a molecular weight of approximately 38 kD to 40 kD, as determined by gel filtration chromatography and SDS/PAGE analyses;
(c) an isoelectric point of approximately 9.1;
(d) possessing heat stability on exposure to temperatures of from ambient to up to and including 65.degree. C. for a period of time of up to and including one hour;
and
(e) capable of inhibiting murine RAW117 lymphoma cell growth.

3 more elements

Dependencies are inferred from the claim text.

Liver-derived tumor cell growth inhibitor

Life of this patent

Liver-derived tumor cell growth inhibitor

Life of this patent

Abstract

Claims14